The $3.1 million increase was due to a $2.2 million increase for personnel costs related to our continued expansion efforts in preparation for the anticipated commercial launch of dalbavancin, an increase of $0.7 million for consultancy related to commercial planning activities and an increase of $0.2 million for occupancy and other operating expenses.